MedTrace Logo

Paclitaxel in Combination With Bevacizumab in Patients With Stage IV NSCLC.

NCT04640935 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 320

Last updated 2020-11-23

No results posted yet for this study

Summary

The aim of the study is to evaluate the paclitaxel-bevacizumab combination retrospectively and multicenter in current practice, with subgroup analyses of the following patients: patients who have previously received immunotherapy, patients with an EGFR or ALK oncogenic addiction pathway, patients who have previously received taxanes or anti-angiogenic agents.

Conditions

  • Non Small Cell Lung Cancer

Sponsors & Collaborators

  • University Hospital, Grenoble

    collaborator OTHER

  • Centre Hospitalier Annecy Genevois

    lead OTHER

Principal Investigators

  • Chantal Decroisette · CH Annecy Genevois

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2020-06-05
Completion
2020-06-05

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04640935 on ClinicalTrials.gov